Exelixis
-
Exelixis Appoints Dana T. Aftab as EVP of Research and Development
Exelixis, Inc. announced the promotion of Dana T. Aftab, Ph.D., to Executive Vice President, Research and Development. Aftab, with 25 years at Exelixis, will lead drug discovery, translational research, product development, and medical affairs. She played a critical role in developing CABOMETYX® (cabozantinib). The company aims to maximize its portfolio, including zanzalintinib. Amy Peterson, M.D., previously Executive Vice President, Product Development & Medical Affairs, has left Exelixis. Exelixis is focused on creating next-generation oncology medicines.
